All section Close
Image Credit: Pixabay
After Graft Row, Bharat Biotech Suspends Brazil Covaxin Deal
Writer: Madhusree Goswami
A mountain girl trying to make it big in the city. She loves to travel and explore and hence keen on doing on-ground stories. Giving the crux of the matter through her editing skills is her way to pay back the journalism its due credit.
India, 24 July 2021 11:54 AM GMT | Updated 24 July 2021 1:00 PM GMT
Editor : Palak Agrawal |
Palak a journalism graduate believes in simplifying the complicated and writing about the extraordinary lives of ordinary people. She calls herself a " hodophile" or in layman words- a person who loves to travel.
Creatives : Madhusree Goswami
A mountain girl trying to make it big in the city. She loves to travel and explore and hence keen on doing on-ground stories. Giving the crux of the matter through her editing skills is her way to pay back the journalism its due credit.
The company's contract with the Brazilian government to procure Covaxin has been a subject of controversy over irregularities that include allegations of an increase in the vaccine's price.
Vaccine manufacturer Bharat Biotech on Friday, July 23, said it has terminated its MoU dated November 24, 2020, with its Brazilian partners (Precisa Medicamantos and Envixia Pharmaceuticals LLC) for Covaxin.
The decision comes days after Brazil suspended its $324 million contract for procuring 20 million doses of Covaxin. The company said it had entered into MOU with Precisa and Envixia to introduce Covaxin in Brazil. However, the company said it will continue to work with ANVISA, the Brazilian drug regulatory body. The company, however, said as part of its global supply outreach, it has offered to supply Covaxin to Brazil.
Meanwhile, Brazil on Saturday, July 24, suspended the proposed clinical trial of Covaxin in the country, reported Hindustan Times.
Background
The corruption allegations pertain to buying the Covaxin doses at steeper rates. To buy vaccines, the Brazilian health ministry needed to pay $320 million (₹2,375 crore approximately) to Precisa Medicamentos, which is representing Bharat Biotech in Brazil. So each dose of Covaxin will cost Brazil $15 (approximately ₹ 1,100). Whistleblowers alleged irregularities while striking the vaccine deal. A former employee at the Brazilian health ministry informed the prosecutor's office that he told President Jair Bolsanaro that he had been pressured to sign a contract that would increase the average price of doses by 1,000 percent.
The official said he was under a great deal of pressure to greenlight the import of the Covaxin vaccine and alleged that there were irregularities in the invoices. On July 2, the Supreme Court judge in Brazil opened a criminal investigation into President Jair Bolsonaro's role in the deal. On their part, both Bolsonaro and Bharat Biotech have denied any wrongdoing.
Also Read: This Woman-Led NGO Is Creating Awareness On Menstrual Heath, Bridging Education Gap In Chandigarh
Must Reads
We are an independent and public-spirited digital media platform for Indian millennials. We report news and issues that matter as well as give you the opportunity to take action.
